Atamparib

DB19028InvestigationalSmall molecule

Atamparib is under investigation in clinical trial NCT05127590 (RBN-2397 in Combination With Pembrolizumab in Patients With SCCL).

Chemical structure of Atamparib
Formula / weight
C20H23F6N7O3 · 523.44 g/mol (avg)
Also known as
3(2h)-pyridazinone, 5-(((1s)-1-methyl-2-(3-oxo-3-(4-(5-(trifluoromethyl)-2-pyrimidinyl)-1-piperazinyl)propoxy)ethyl)amino)-4-(trifluoromethyl)- · 5-(((2s)-1-(3-oxo-3-(4-(5-(trifluoromethyl)pyrimidin-2- yl)piperazin-1-yl)propoxy)propan-2-yl)amino)-4- (trifluoromethyl)pyridazin-3(2h)-one
Code names
RBN-2397

Resolves to

Compound
UNIIB1MW2ME77ACAS2381037-82-5ChEMBLCHEMBL5095043
Structure
InChIKeyUQZCQKXJAXKZQH-LBPRGKRZSA-NSMILESC[C@@H](COCCC(=O)N1CCN(CC1)C1=NC=C(C=N1)C(F)(F)F)NC1=C(C(=O)NN=C1)C(F)(F)F
Targets
Q7Z3E1TIPARP

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
3Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which drugs share a target with Atamparib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In